Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
PT-141
Clinical
FDA-approved (specific use)
Summary
Melanocortin agonist approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women; also used off-label in men in clinics/forums.
Categories
Sexual Health
Mechanism
Primarily MC4R (and related) agonism in the CNS influencing sexual desire and arousal circuitry.
Half-life
~2.7 hours (bremelanotide)
Routes
Subcutaneous injection; Intranasal
Legal / access
FDA-approved as Vyleesi for HSDD in premenopausal women. Other formulations/uses may be off-label or unapproved.
Key risks
- Nausea
- Flushing
- Headache
- Transient blood-pressure/heart-rate changes
Common claims
- Desire-based libido boost (not just erection)
- Works when PDE5 inhibitors feel insufficient
- Couple intimacy enhancement narratives
Select peptide B